Cargando…

A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment

Detalles Bibliográficos
Autores principales:	Alis, Ceren, Emre, Dogukan Hazar, Karaali Savrun, Feray, Gunduz, Aysegul, Uzun Adatepe, Nurten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078630/ https://www.ncbi.nlm.nih.gov/pubmed/35525875 http://dx.doi.org/10.1007/s10072-022-06108-6

Ejemplares similares

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
por: Mimori, Masahiro, et al.
Publicado: (2022)

Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19
por: Scopelliti, Giuseppe, et al.
Publicado: (2020)

Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic
por: Ricciardi, Dario, et al.
Publicado: (2021)

An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis
por: Wang, H.Y., et al.
Publicado: (2023)

The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis
por: Galassi, Giuliana
Publicado: (2022)

COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation
por: Trinchillo, Assunta, et al.
Publicado: (2022)

COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined
por: Kim, Sohyeon, et al.
Publicado: (2023)

Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review
por: Rodrigues, Cleonisio Leite, et al.
Publicado: (2022)

Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
por: Nóbrega, Paulo Ribeiro, et al.
Publicado: (2022)

Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

Reply to Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
por: Galassi, Giuliana, et al.
Publicado: (2022)

An unusual case of vascular loop syndrome
por: Uluduz, Derya, et al.
Publicado: (2007)

New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series
por: Fanella, Gaia, et al.
Publicado: (2022)

Autonomic and neuropathic complaints of long-COVID objectified: an investigation from electrophysiological perspective
por: Ser, Merve Hazal, et al.
Publicado: (2022)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report
por: Moschella, Phillip, et al.
Publicado: (2020)

Episodic parieto-occipital idiopathic stabbing headache-like pain: a case report
por: Göksan, Baki, et al.
Publicado: (2002)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2020)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Pulmonary Embolism and Acute Psychosis, a Case Report of an Outpatient with a Mild Course of COVID-19
por: Makivic, Nina, et al.
Publicado: (2021)

Analysis of neurology consultations in hospitalized patients with COVID-19
por: Ser, Merve Hazal, et al.
Publicado: (2022)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab
por: Weidmayer, Sara L., et al.
Publicado: (2023)

Genesis of arrhythmia in the course of COVID-19
por: Szarpak, Lukasz, et al.
Publicado: (2022)

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
por: Vu, Tuan, et al.
Publicado: (2021)

Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
por: Katyal, Nakul, et al.
Publicado: (2021)

Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series
por: Kang, Seung Ah, et al.
Publicado: (2022)

The importance of early detection of ENT symptoms in mild-to-moderate COVID-19
por: Spinato, Giacomo, et al.
Publicado: (2021)

Myasthenia Gravis during the Course of Neuromyelitis Optica
por: Etemadifar, Masoud, et al.
Publicado: (2011)

An online course on applied biochemistry and molecular biology through case‐based learning
por: Plasencia, Javier
Publicado: (2022)

Spinal myoclonus following a peripheral nerve injury: a case report
por: Savrun, Feray Karaali, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_k595vtk65turvco3mgj1bo3r0r